# 2026-15624: DEA Clamps Down on PMK Glycidic Acid Esters for Drug Labs

2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2026-08-03, effective Comments must be submitted electronically or postmarked on or before September 2, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept any comments after 11:59 p.m. Eastern Time on the last day of the comment period.; PRIA reads it as touching household money (as of 2026-08-10).

- Canonical: https://policyrisk.com/federal-register/2026-15624
- As of: 2026-08-10
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-15624
- Title: Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 48786
- Published: 2026-08-03
- Effective: Comments must be submitted electronically or postmarked on or before September 2, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept any comments after 11:59 p.m. Eastern Time on the last day of the comment period.
- Comments close: 2026-09-02
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-08-10

## In one line

DEA Clamps Down on PMK Glycidic Acid Esters for Drug Labs

## Summary

The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.

## Effects PRIA read

- Seven Esters Added to List I: cost, high. DEA proposes to add esters of 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) — specifically the ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl esters — to the List I chemical listing. If finalized, these esters, when not already listed elsewhere in the Controlled Substan…
- Any Quantity or Mixture Regulated: cost, medium. DEA proposes that chemical mixtures containing any amount of the esters of 3,4-MDP-2-P methyl glycidic acid (not listed elsewhere in the CSA) would not be exempt at any concentration. All transactions of such esters or mixtures, regardless of size or concentration, would be regulated unless a manuf…
- Registration, Reporting, and Penalties: cost, high. If finalized, persons who manufacture, distribute, import, or export these esters must obtain DEA registration and comply with recordkeeping, reporting, import/export rules, security requirements, and allow administrative inspections; unauthorized activities may result in civil or criminal penaltie…
- Chemical-Mixture Exemption Route Exists: benefit, low. Manufacturers may apply for an exemption of a chemical mixture under 21 CFR 1310.13; DEA may grant an exemption by final rule if it determines the mixture cannot be readily used to make illicit controlled substances and the listed chemical cannot be readily recovered. This provides a formal—but dis…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-20750](https://policyrisk.com/federal-register/2026-20750): L Krenk DBA Maui Clinic Pharmacy; Decision and Order, 2026-10-09
- [2026-20757](https://policyrisk.com/federal-register/2026-20757): Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products, 2026-10-09

## Sources
- [2026-15624 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/03/2026-15624/amendment-to-34-mdp-2-p-methyl-glycidic-acid-a-list-i-chemical)
- [2026-15624 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15624.pdf)

## Related
- [Previous: 2026-15614, Section 898(c) Transition Rule for Allocating Foreign Taxes and Section 960(d)(…](https://policyrisk.com/federal-register/2026-15614)
- [Next: 2026-15657, Amendment of Class D and Class E Airspace; Morgantown, WV: Withdrawal](https://policyrisk.com/federal-register/2026-15657)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-15624 (as of 2026-08-10).